# PT003 MDI Cardiovascular Safety Study

> **NCT01349803** · PHASE2 · COMPLETED · sponsor: **Pearl Therapeutics, Inc.** · enrollment: 237 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** PT005 MDI
- **DRUG:** PT001 MDI
- **DRUG:** PT003 MDI
- **DRUG:** Formoterol Fumarate 12 μg (Foradil® Aerolizer®)

## Key facts

- **NCT ID:** NCT01349803
- **Lead sponsor:** Pearl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 237 (ACTUAL)
- **Last updated:** 2017-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01349803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01349803, "PT003 MDI Cardiovascular Safety Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01349803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*